Sacrocolpopexy

Sacrocolpopexy restores vaginal apical support by attaching mesh to the vagina and securing it to the anterior longitudinal ligament over the sacrum. It is an established option for symptomatic vaginal vault prolapse, particularly when durable support and preservation of vaginal length are important. Choice among abdominal mesh repair, vaginal native-tissue suspension and other treatments depends on symptoms, anatomy, operative risk and the patient's priorities.^[1][2][3]

For the overall decision framework, see Prolapse Repair Principles. Related operations have separate pages: Supracervical Hysterectomy at Sacrocolpopexy, Sacrohysteropexy and Pectopexy.

Patient Selection and Planning

Consider sacrocolpopexy for bothersome apical prolapse when the patient chooses reconstructive surgery after discussion of nonsurgical and surgical options. Recurrent prolapse, substantial anterior/apical descent, prior surgery and vaginal length help shape that discussion; a single age or BMI threshold does not determine the operation.^[1][2]

Before surgery, document:

• Symptoms and support: bulge bother, POP-Q, vaginal length, compartment defects, bowel symptoms and sexual goals.
• Urinary function: stress and urgency leakage, emptying symptoms and prolapse-reduction stress testing when relevant to continence planning.
• Previous treatment: operative reports, prior mesh or graft, hysterectomy status and complications.
• Operative suitability: abdominal access, ability to tolerate the planned positioning/anesthesia, healing risks, and the feasibility of a vaginal alternative.
• Patient preferences: permanent mesh, uterine/cervical preservation, recovery priorities and willingness to accept possible future treatment.^[1][2]

Counsel about recurrent prolapse, mesh exposure, urinary or bowel dysfunction, pain/dyspareunia, organ or vascular injury and possible further surgery. Mesh implanted abdominally for sacrocolpopexy is a different procedure from transvaginal mesh implantation for prolapse.^[1][3][8]

Mesh and Fixation

Sacrocolpopexy mesh supportOriginal schematic · v2026-09-12 · Clinical review pending

Conceptual attachment diagram, not to scale. It illustrates vaginal mesh arms and sacral attachment; it does not specify dissection depth, suture placement or an individual patient's final vaginal position.

Component	Practical interpretation
Mesh	Macroporous monofilament polypropylene is the usual synthetic material. Mesh weight, porosity and configuration matter; a product's favorable short-term results do not establish lifelong safety.[1][7][13]
Vaginal attachment	Absorbable sutures are a reasonable option. Comparative evidence has not shown worse short-term support and suggests less suture exposure than permanent sutures; it does not show that mesh exposure is eliminated.[5][6]
Sacral attachment	Permanent fixation to the anterior longitudinal ligament is commonly used. Evidence about vaginal suture choice cannot be transferred to sacral fixation.[1][2][6]
Graft alternatives	Biologic grafts are less well studied and may be less durable. They are not an established substitute that automatically solves impaired healing or mesh risk; consider the entire procedure and native-tissue alternatives.[1][13]
Peritoneal coverage	Cover the mesh and manage exposed suture/barbed ends to limit bowel contact. Closure must avoid bowel entrapment and tension on adjacent structures.[1][2]

The 2023 Pollack systematic review found no detected difference in sacrocolpopexy success in its direct comparisons of permanent and absorbable vaginal sutures (RR 1.00, 95% CI 0.98–1.03). Most included evidence was observational and follow-up was relatively short. Do not interpret pooled single-arm success percentages as a randomized comparison.^[5]

In the 150-patient Tagliaferri trial, polyglactin 910 was compared with braided polyester during laparoscopic sacrocervicopexy with supracervical hysterectomy. Both arms used permanent sacral fasteners. At one year, mesh exposures were 0/75 versus 3/75; the difference was not statistically significant and the trial was not powered to establish rare-complication safety. This is not evidence for absorbable fixation at every attachment site.^[6]

Open, Laparoscopic and Robotic Approaches

Minimally invasive access can reduce the burden of an abdominal incision and shorten recovery. Open surgery remains an option when clinical circumstances favor it. The operative route should reflect the patient's needs and the surgeon/team's experience.^[1][2]

Robotic assistance has not been shown to confer universally better clinical outcomes than conventional laparoscopy. The 2026 Ferrari review found no clear difference in several reported outcomes, but the evidence combines randomized and observational reports, heterogeneous techniques and follow-up. Its reported lower conversion rate with robotics comes from observational cohorts. These findings do not prove equivalence or establish a causal advantage in complex cases.^[4]

Port layout, robotic platform, retraction and instruments vary. A fixed port diameter, mandatory manipulator or numerical learning-curve cutoff should not be treated as a requirement for every operation. Training and observed competence include dissection, fixation, recognition of injury and management of complications.^[1][2]

Operative Sequence

The following describes core laparoscopic/robotic steps. Sequence, mesh configuration and the extent of dissection vary with vault versus cervical attachment, compartment defects, scars and tissue quality.^[2][13]

1. Position and expose. Use protected lithotomy and the Trendelenburg needed for access, within anesthetic tolerance. Establish abdominal access and retract bowel under direct vision. A vaginal sizer or other retractor can define the vault when useful; it is not required in every configuration.
2. Identify sacral landmarks. Identify the right ureter, iliac vessels and middle sacral vessels. Expose the anterior longitudinal ligament sufficiently for controlled fixation while limiting presacral dissection. Avoid the L5–S1 disc and deep bites into underlying structures.
3. Develop the vaginal planes. Separate bladder anteriorly and rectum posteriorly from the vagina. Tailor distal dissection to the defect and planned attachment; protect the vaginal wall and adjacent organs. Routine deep levator attachment or dissection to a fixed bladder landmark is not a universal requirement.
4. Attach the mesh. Spread the vaginal portions smoothly and secure them to supportive tissue without excessive tightening. The number and distribution of sutures depend on the mesh and anatomy. Inspect for vaginal epithelial penetration and correct misplaced sutures.
5. Set sacral attachment and support. Secure the mesh stem to the identified ligament with controlled fixation. Assess vaginal length, axis and support while avoiding excessive traction, constriction or distortion. No single ischial-spine target substitutes for assessment of the reconstruction.
6. Cover and inspect. Close the peritoneal opening over the mesh when feasible, account for exposed suture ends, and inspect hemostasis and bowel relationships. Reassess any recognized organ injury and its implications for the planned reconstruction.
7. Check urinary integrity. Perform cystoscopic assessment of the bladder and ureteral efflux, and investigate an abnormal finding before completion. Document the implant, fixation and any concomitant procedures.^[1][2][13]

Sacral fixation deserves particular care: spondylodiscitis is a recognized, uncommon complication, rather than a theoretical concern restricted to one fixation device. Persistent severe back pain, especially with systemic symptoms, warrants assessment after surgery.^[1][2][13]

Efficacy: Read the Endpoint Before the Percentage

ASPIRe: post-hysterectomy vault prolapse

The ASPIRe trial randomized 376 women with symptomatic prolapse after total hysterectomy to sacrocolpopexy, vaginal native-tissue repair or transvaginal mesh repair; 360 underwent surgery. Its primary endpoint was the first occurrence of retreatment, prolapse beyond the hymen or bothersome vaginal bulge.^[3]

Three-year modelled composite failure	Sacrocolpopexy	Native-tissue repair	Transvaginal mesh
Adjusted estimate	28%	43%	29%

Sacrocolpopexy had lower failure than native-tissue repair (adjusted HR 0.57; 99% CI 0.33–0.98; P=.008). The transvaginal-mesh arm met its prespecified noninferiority comparison with sacrocolpopexy, but did not demonstrate superiority over native-tissue repair at the trial's adjusted significance threshold. Noninferiority is not equivalence; the Uphold LITE transvaginal device is no longer marketed in the United States.^[3]

Composite failure was much more common than retreatment: from six months through final follow-up, 5/120 sacrocolpopexy participants received additional prolapse treatment. Some failures were examination findings alone. Prior prolapse mesh/grafts and several higher-risk conditions were excluded, limiting generalization.^[3]

Primary uterovaginal prolapse

When hysterectomy is chosen for primary uterovaginal prolapse, the September 2026 U-POP review adds evidence favoring sacrocolpopexy durability. Its largely observational, study-arm comparisons do not establish a universal operative mandate.

Longer-term outcomes

In E-CARE, the extension of an older open abdominal sacrocolpopexy trial, estimated seven-year anatomic failure was 27% with Burch and 22% without Burch; composite failure was 48% and 34%, respectively. These estimates use different definitions from ASPIRe and have substantial uncertainty and attrition: 215 entered the extension and 126 completed seven-year follow-up. They do not mean that this proportion required another operation.^[8]

Counsel with separate outcomes: relief of bulge, anatomic support, urinary/bowel and sexual function, retreatment, and mesh-related harm. Follow-up duration and ascertainment materially change the percentages.^[3][7][8]

Complications and Follow-up

Early concerns include hemorrhage, bladder/ureter/bowel injury, ileus or bowel obstruction, infection, thromboembolism and voiding dysfunction. Later concerns include recurrent prolapse, new urinary or bowel symptoms, pain/dyspareunia, suture exposure and mesh complications. Avoid applying one historical pooled rate across all contemporary patients and materials.^[1][2][8]

Mesh exposure can present years after repair. In the 2024 e-PACT II follow-up of minimally invasive total hysterectomy and sacrocolpopexy, cumulative mesh exposure was 18/182 (9.9%) at mean 5.3 years, incorporating earlier exposure events. Only 82 of the original 200 participated at this follow-up, and 56 underwent examination. The reported 95% success applies to these participants, not all original patients. This study neither compares total with supracervical hysterectomy nor proves zero risk with a particular suture.^[7]

E-CARE estimated mesh erosion at 10.5% by seven years (95% CI 6.8–16.1), using older and varied operative materials. This is a separate population and method, not a direct comparison with e-PACT II.^[8]

Review healing and bladder emptying, then assess symptoms and support over time. New bleeding, persistent discharge, pain, dyspareunia or recurrent urinary symptoms should prompt examination and appropriate evaluation. Mesh exposure, organ erosion, infection and pain without visible exposure are different problems and may require different management.^[1][7][8]

Concomitant Hysterectomy and Other Repairs

Choose among total hysterectomy, supracervical hysterectomy and uterine preservation according to uterine/cervical pathology, screening needs, anatomy and patient preference. Historical exposure findings do not justify a blanket instruction to avoid total hysterectomy, and retention of the cervix does not eliminate mesh risk. Discuss the tradeoffs for the actual mesh and operation being planned.^[2][7][13]

See Supracervical Hysterectomy at Sacrocolpopexy and Sacrohysteropexy. Additional vaginal repair or a combined colorectal procedure should address a demonstrated defect or symptom and be planned with the relevant specialist; it is not a routine package for every sacrocolpopexy.^[2]

Concomitant Anti-Incontinence Procedures

Discuss existing symptomatic SUI separately from occult leakage on prolapse reduction and prophylaxis in a woman without preoperative SUI symptoms. Combined and staged procedures have different tradeoffs.^[9][11]

In CARE, 322 women without preoperative SUI symptoms were randomized during open abdominal sacrocolpopexy. After the journal's 2016 coding correction, the three-month composite SUI endpoint was 33.6% with Burch versus 57.4% without Burch. This includes symptoms, stress testing or treatment and is not a universal risk of bothersome leakage.^[9][10]

The 2026 Cochrane review describes uncertainty and inconsistency in prophylactic Burch evidence for stress-continent women. Its more favorable concomitant-sling findings concern different populations and procedures. Do not assume the same benefit for every laparoscopic or robotic reconstruction. See Burch's evidence discussion.^[11]

Postoperative Recovery

Encourage early mobilization and give a recovery plan based on the operation, complications and the patient's function. Routine prolonged home rest is not supported by the available recovery evidence.^[1][12]

The 2023 O'Shea randomized trial assigned 123 women to standard restrictions or expedited activity after minimally invasive apical prolapse surgery; 107 completed the primary analysis, including 48 who underwent robotic sacrocolpopexy. Expedited instructions produced noninferior anatomic and symptom outcomes at three months. Both groups avoided sexual activity until the six-week visit.^[12]

This supports a more flexible return to ordinary physical activity after uncomplicated surgery. It does not establish two-year safety from that report, immediate unrestricted heavy manual work, or early vaginal intercourse. The study selected women with reasonable baseline mobility, and measured postoperative activity was similar despite different instructions.^[12]

References

1. Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Sacrocolpopexy: clinical guidance statement (C-Gyn 37). Version 1.1, 2022. Guidance.

2. Culligan PJ, Saiz CM, Rosenblatt PL. Contemporary use and techniques of laparoscopic sacrocolpopexy with or without robotic assistance for pelvic organ prolapse. Obstet Gynecol. 2022;139:922-932. doi:10.1097/AOG.0000000000004761.

3. Menefee SA, Richter HE, Myers D, et al. Apical suspension repair for vaginal vault prolapse: a randomized clinical trial. JAMA Surg. 2024;159:845-855. doi:10.1001/jamasurg.2024.1206. Figure-label correction.

4. Ferrari A, Borrelli M, Moretti G, et al. Laparoscopic versus robot-assisted sacrocolpopexy: a systematic review and meta-analysis. BJOG. 2026. doi:10.1111/1471-0528.70218.

5. Pollack BL, Popiel P, Toaff MC, et al. Permanent compared with absorbable suture in apical prolapse surgery: a systematic review and meta-analysis. Obstet Gynecol. 2023;141:268-283. doi:10.1097/AOG.0000000000005032.

6. Tagliaferri V, Ruggieri S, Taccaliti C, et al. Comparison of absorbable and permanent sutures for laparoscopic sacrocervicopexy: a randomized controlled trial. Acta Obstet Gynecol Scand. 2021;100:347-352. doi:10.1111/aogs.13997.

7. Bretschneider CE, Myers ER, Geller EJ, Kenton KS, Henley BR, Matthews CA. Long-term mesh exposure 5 years following minimally invasive total hysterectomy and sacrocolpopexy. Int Urogynecol J. 2024;35:901-907. doi:10.1007/s00192-024-05769-5.

8. Nygaard I, Brubaker L, Zyczynski HM, et al. Long-term outcomes following abdominal sacrocolpopexy for pelvic organ prolapse. JAMA. 2013;309:2016-2024. doi:10.1001/jama.2013.4919. Time-unit correction.

9. Brubaker L, Cundiff GW, Fine P, et al. Abdominal sacrocolpopexy with Burch colposuspension to reduce urinary stress incontinence. N Engl J Med. 2006;354:1557-1566. doi:10.1056/NEJMoa054208.

10. Brubaker L, Brown MB, Weber AM, NICHD Pelvic Floor Disorders Network Investigators. Corrections to report of a trial of Burch colposuspension. N Engl J Med. 2016;374:2295. doi:10.1056/NEJMc1605817.

11. Baessler K, Christmann-Schmid C, Haya N, et al. Surgery for women with pelvic organ prolapse with or without stress urinary incontinence. Cochrane Database Syst Rev. 2026;2:CD013108. doi:10.1002/14651858.CD013108.pub2.

12. O'Shea M, Siddiqui NY, Truong T, Erkanli A, Barber MD. Standard restrictions vs expedited activity after pelvic organ prolapse surgery: a randomized clinical trial. JAMA Surg. 2023;158:797-805. doi:10.1001/jamasurg.2023.1649.

13. Shahid U, Chen Z, Maher C. Sacrocolpopexy: the way I do it. Int Urogynecol J. 2024;35:2107-2123. doi:10.1007/s00192-024-05922-0.